secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2023-09-22T23:59:59+00:00
Accession:  0001493152-23-033498
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma receives NYSE American deficiency notice for low price; must cure by Mar 2024
--------------------------------------------------------------------------------

- Received NYSE American deficiency letter for non-compliance with Section 1003(f)(v) due to 30-day avg closing price below $0.20.
- Must demonstrate sustained price improvement or effect reverse stock split by March 21, 2024 to regain compliance.
- Common stock continues trading on NYSE American under symbol MTNB; no immediate delisting.
- Company is actively engaging with Exchange and developing plans to cure within the cure period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223033498/0001493152-23-033498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223033498/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-033498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer